PDE9A inhibition rescues amyloid beta-induced deficits in synaptic plasticity and cognition

Neurobiology of Aging

Volumn 35, Issue 9, 2014, Pages 2072-2078

  Kroker, Katja S ^a   Mathis, Chantal ^b   Marti, Anelise ^a   Cassel, Jean Christophe ^b   Rosenbrock, Holger ^a   Dorner Ciossek, Cornelia ^a  

^a BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^b UNIVERSITÉ DE STRASBOURG   (France)

Author keywords

Alzheimer's disease; Amyloid beta; BAY 73 6691; CGMP; Cognition; Hippocampus; LTP; Object location task; PDE9; Tg2576

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-42]; BAY 73 6691; PHOSPHODIESTERASE; PHOSPHODIESTERASE INHIBITOR; PROTEIN PDE9A; UNCLASSIFIED DRUG; AMYLOID BETA-PROTEIN (1-42); BAY 73-6691; CYCLIC AMP PHOSPHODIESTERASE; CYCLIC GMP; PDE9A PROTEIN, HUMAN; PEPTIDE FRAGMENT; PYRAZOLE DERIVATIVE; PYRIMIDINE DERIVATIVE;

AMYLOIDOSIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN REGION; COGNITION; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; ENZYME INHIBITION; HIPPOCAMPUS; LONG TERM POTENTIATION; MEMORY CONSOLIDATION; NERVE CELL PLASTICITY; NONHUMAN; PHARMACOLOGICAL BLOCKING; PRIORITY JOURNAL; PROTEIN SYNTHESIS; RAT; TASK PERFORMANCE; ALZHEIMER DISEASE; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; GENETICS; MALE; MEMORY; METABOLISM; MOLECULARLY TARGETED THERAPY; MOUSE; PHYSIOLOGY; PSYCHOLOGY; TRANSGENIC MOUSE; WISTAR RAT;

3',5'-CYCLIC-AMP PHOSPHODIESTERASES; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; COGNITION; CYCLIC GMP; HIPPOCAMPUS; LONG-TERM POTENTIATION; MALE; MEMORY; MICE; MICE, TRANSGENIC; MOLECULAR TARGETED THERAPY; NEURONAL PLASTICITY; PEPTIDE FRAGMENTS; PYRAZOLES; PYRIMIDINES; RATS, WISTAR;

EID: 84902104193     PISSN: 01974580     EISSN: 15581497     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2014.03.023     Document Type: Article

References (66)

1. Alzheimer's disease facts and figures. Alzheimers Dement. 2012, 8:131-168. Alzheimer's Association.
2. Andreeva S.G., Dikkes P., Epstein P.M., Rosenberg P.A. Expression of cGMP-specific phosphodiesterase 9A mRNA in the rat brain. J.Neurosci. 2001, 21:9068-9076.
3. Assini F.L., Duzzioni M., Takahashi R.N. Object location memory in mice: pharmacological validation and further evidence of hippocampal CA1 participation. Behav. Brain Res. 2009, 204:206-211.
4. Blennow K., de Leon M.J., Zetterberg H. Alzheimer's disease. Lancet 2006, 368:387-403.
5. Bliss T.V.P., Collingridge G.L. Asynaptic model of memory: long-term potentiation in the hippocampus. Nature 1993, 361:31-39.
6. Blokland A., Menniti F.S., Prickaerts J. PDE inhibition and cognition enhancement. Expert Opin. Ther. Pat 2012, 22:349-354.
7. Blokland A., Schreiber R., Prickaerts J. Improving memory: a role for phosphodiesterases. Curr. Pharm. Des. 2006, 12:2511-2523.
8. Burgess N., Maguire E.A., O'Keefe J. The human hippocampus and spatial and episodic memory. Neuron 2002, 35:625-641.
9. Christopherson K.S., Hillier B.J., Lim W.A., Bredt D.S. PSD-95 assembles a ternary complex with the N-methyl-D-aspartic acid receptor and a bivalent neuronal NO synthase PDZ domain. J.Biol. Chem. 1999, 274:27467-27473.
10. Deshmukh S.S., Knierim J.J. Influence of local objects on hippocampal representations: landmark vectors and memory. Hippocampus 2013, 23:253-267.
11. Domek-Łopacińska K.U., Strosznajder J.B. Cyclic GMP and nitric oxide synthase in aging and Alzheimer's disease. Mol. Neurobiol. 2010, 41:129-137.
12. Esparza T.J., Zhao H., Cirrito J.R., Cairns N.J., Bateman R.J., Holtzman D.M., Brody D.L. Amyloid-beta oligomerization in Alzheimer dementia versus high-pathology controls. Ann. Neurol. 2013, 73:104-119.
13. Ferreira S.T., Klein W.L. The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer's disease. Neurobiol. Learn. Mem. 2011, 96:529-543.
14. Fisher D.A., Smith J.F., Pillar J.S., St Denis S.H., Cheng J.B. Isolation and characterization of PDE9A, a novel human cGMP specific phosphodiesterase. J.Biol. Chem. 1998, 25:15559-15564.
15. Fleischman D.A., Gabrieli J. Long-term memory in Alzheimer's disease. Curr. Opin. Neurobiol. 1999, 9:240-244.
16. Francis P.T., Palmer A.M., Snape M., Wilcock G.K. The cholinergic hypothesis of Alzheimer's disease: a review of progress. J.Neurol. Neurosurg. Psychiatry 1999, 66:137-147.
17. Freir D.B., Fedriani R., Scull D., Smith I.M., Selkoe D.J., Walsh D.M., Regan C.M. Aβ oligomers inhibit synapse remodeling necessary for memory consolidation. Neurobiol. Aging 2011, 32:2211-2218.
18. Frisoni G.B., Ganzola R., Canu E., Rüb U., Pizzini F.B., Alessandrini F., Zoccatelli G., Beltramello A., Caltagirone C., Thompson P.M. Mapping local hippocampal changes in Alzheimer's disease and normal ageing with MRI at 3 Tesla. Brain 2008, 131:3266-3276.
19. Garthwaite J. Concepts of neural nitric oxide-mediated transmission. Eur. J. Neurosci. 2008, 27:2783-2802.
20. Haass C., Selkoe D.J. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid β-peptide. Nat. Rev. Mol. Cell Biol. 2007, 8:101-112.
21. Hsiao K., Chapman P., Nilsen S., Eckman C., Harigaya Y., Younkin S., Yang F., Cole G. Correlative memory deficits, Aβ elevation, and amyloid plaques in transgenic mice. Science 1996, 274:99-102.
22. Hutson P.H., Finger E.N., Magliaro B.C., Smith S.M., Converso A., Sanderson P.E., Mullins D., Hyde L.A., Eschle B.K., Turnbull Z., Sloan H., Guzzi M., Zhang X., Wang A., Rindgen D., Mazzola R., Vivian J.A., Eddins D., Uslaner J.M., Bednar R., Gambone C., Le-Mair W., Marino M.J., Sachs N., Xu G., Parmentier-Batteur S. The selective phosphodiesterase 9 (PDE9) inhibitor PF-04447943 (6-[(3S,4S)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-1-(tetrahydro-2H-pyran-4-yl)-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one) enhances synaptic plasticity and cognitive function in rodents. Neuropharmacology 2011, 61:665-676.
23. 2+ entry through non-alpha7 nicotinic acetylcholine receptors. Eur. J. Neurosci. 2010, 31:463-476.
24. Kar S., Slowikowski S.P., Westaway D., Mount H.T. Interactions between β-amyloid and central cholinergic neurons: implications for Alzheimer's disease. J.Psychiatry Neurosci. 2004, 29:427-441.
25. Kawarabayashi T., Shoji M., Younkin L.H., Wen-Lang L., Dickson D.W., Murakami T., Matsubara E., Abe K., Ashe K.H., Younkin S.G. Dimeric amyloid beta protein rapidly accumulates in lipid rafts followed by apolipoprotein E and phosphorylated tau accumulation in the Tg2576 mouse model of Alzheimer's disease. J.Neurosci. 2004, 24:3801-3809.
26. Kawarabayashi T., Younkin L.H., Saido T.C., Shoji M., Ashe K.H., Younkin S.G. Age-dependent changes in brain, CSF, and plasma amyloid (beta) protein in the Tg2576 transgenic mouse model of Alzheimer's disease. J.Neurosci. 2001, 21:372-381.
27. Kessels R.P., Rijken S., Joosten-Weyn Banningh L.W., Van Schuylenborgh-VAN Es N., Olde Rikkert M.G. Categorical spatial memory in patients with mild cognitive impairment and Alzheimer dementia: positional versus object-location recall. J.Int. Neuropsychol. Soc. 2010, 16:200-204.
28. Kleiman R.J., Chapin D.S., Christoffersen C., Freeman J., Fonseca K.R., Geoghegan K.F., Grimwood S., Guanowsky V., Hajós M., Harms J.F., Helal C.J., Hoffmann W.E., Kocan G.P., Majchrzak M.J., McGinnis D., McLean S., Menniti F.S., Nelson F., Roof R., Schmidt A.W., Seymour P.A., Stephenson D.T., Tingley F.D., Vanase-Frawley M., Verhoest P.R., Schmidt C.J. Phosphodiesterase 9A regulates central cGMP and modulates responses to cholinergic and monoaminergic perturbation invivo. J.Pharmacol. Exp. Ther. 2012, 341:396-409.
29. Klein W.L. Synaptotoxic amyloid-β oligomers: a molecular basis for the cause, diagnosis, and treatment of Alzheimer's disease?. J.Alzheimers Dis. 2013, 33(Suppl. 1):S49-S65.
30. Ko G.Y., Kelly P.T. Nitric oxide acts as a postsynaptic signaling molecule in calcium/calmodulin-induced synaptic potentiation in hippocampal CA1 pyramidal neurons. J.Neurosci. 1999, 19:6784-6794.
31. Kroker K.S., Moreth J., Kussmaul L., Rast G., Rosenbrock H. Restoring long-term potentiation impaired by amyloid-beta oligomers: comparison of an acetylcholinesterase inhibitior and selective neuronal nicotinic receptor agonists. Brain Res. Bull. 2013, 96:28-38.
32. Kroker K.S., Rast G., Giovannini R., Marti A., Dorner-Ciossek C., Rosenbrock H. Inhibition of acetylcholinesterase and phosphodiesterase-9A has differential effects on hippocampal early and late LTP. Neuropharmacology 2012, 62:1964-1974.
33. Kroker K.S., Rast G., Rosenbrock H. Differential effect of the mGlu5 receptor positive allosteric modulator ADX-47273 on early and late hippocampal LTP. Neuropharmacology 2011, 61:707-714.
34. Kroker K.S., Rosenbrock H., Rast G. Amulti-slice recording system for stable late phase hippocampal long-term potentiation experiments. J.Neurosci. Methods 2011, 194:394-401.
35. Lacor P.N., Buniel M.C., Furlow P.W., Sanz Clemente A., Velasco P.T., Wood M., Viola K.L., Klein W.L. Aβ oligomer-induced aberrations in synapse composition, shape, and density provide a molecular basis for loss of connectivity in Alzheimer's disease. J.Neurosci. 2007, 27:796-807.
36. Lakics V., Karran E.H., Boess F.G. Quantitative comparison of phosphodiesterase mRNA distribution in human brain and peripheral tissues. Neuropharmacology 2010, 59:367-374.
37. 1-42 are potentcentral nervous system neurotoxins. Proc. Natl. Acad. Sci. U.S.A 1998, 95:6448-6453.
38. Lee A.C., Rahman S., Hodges J.R., Sahakian B.J., Graham K.S. Associative and recognition memory for novel objects in dementia: implications for diagnosis. Eur. J. Neurosci. 2003, 18:1660-1670.
39. Lu Y.F., Kandel E.R., Hawkins R.D. Nitric oxide signaling contributes to late-phase LTP and CREB phosphorylation in the hippocampus. J.Neurosci. 1999, 19:10250-10261.
40. MacDuffie K.E., Atkins A.S., Flegal K.E., Clark C.M., Reuter-Lorenz P.A. Memory distortion in Alzheimer's disease: deficient monitoring of short- and long-term memory. Neuropsychology 2012, 26:509-516.
41. Menniti F.S., Faraci W.S., Schmidt C.J. Phosphodiesterases in the CNS: targets for drug development. Nat. Rev. Drug Discov. 2006, 5:660-670.
42. Moreth J., Kroker K.S., Schwanzar D., Schnack C., von Arnim C.A., Hengerer B., Rosenbrock H., Kussmaul L. Globular and protofibrillar Aβ aggregates impair neurotransmission by different mechanisms. Biochemistry 2013, 52:1466-1476.
43. Nicholas T., Evans R., Styren S., Qiu R., Wang E.Q., Nelson F., Le V., Grimwood S., Christoffersen C., Banerjee S., Corrigan B., Kocan G., Geoghegan K., Carrieri C., Raha N., Verhoest P., Soares H. PF-04447943, a novel PDE9A inhibitor, increases cGMPlevels in cerebrospinal fliud: translation from non-clinical species to healthy human volunteers. Alzheimer Demen. 2009, 5:330-331.
44. Nimmrich V., Ebert U. Is Alzheimer's disease a result of presynaptic failure? Synaptic dysfunctions induced by oligomeric β-amyloid. Rev. Neurosci. 2009, 20:1-12.
45. Nomura I., Takechi H., Kato N. Intraneuronally injected amyloid beta inhibits long-term potentiation in rat hippocampal slices. J.Neurophysiol. 2012, 107:2526-2531.
46. Piekema C., Kessels R.P., Mars R.B., Petersson K.M., Fernández G. The right hippocampus participates in short-term memory maintenance of object-location associations. Neuroimage 2006, 33:374-382.
47. Pihlajamäki M., Tanila H., Könönen M., Hänninen T., Hämäläinen A., Soininen H., Aronen H.J. Visual presentation of novel objects and new spatial arrangements of objects differentially activates the medial temporal lobe subareas in humans. Eur. J. Neurosci. 2004, 19:1939-1949.
48. Prickaerts J., Sik A., van Staveren W.C., Koopmans G., Steinbusch H.W., van der Staay F.J., de Vente J., Blokland A. Phosphodiesterase type 5 inhibition improves early memory consolidation of object information. Neurochem. Int. 2004, 45:915-928.
49. Querfurth H.W., LaFerla F.M. Alzheimer's disease. N.Engl. J. Med. 2010, 362:329-344.
50. Reed M.N., Hofmeister J.J., Jungbauer L., Welzel A.T., Yu C., Sherman M.A., Lesné S., LaDu M.J., Walsh D.M., Ashe K.H., Cleary J.P. Cognitive effects of cell-derived and synthetically derived Aβ oligomers. Neurobiol. Aging 2011, 32:1784-1794.
51. Reneerkens O.A., Rutten K., Steinbusch H.W., Blokland A., Prickaerts J. Selective phosphodiesterase inhibitors: a promising target for cognition enhancement. Psychopharmacology (Berl) 2009, 202:419-443.
52. Rutten K., Prickaerts J., Hendrix M., van der Staay F.J., Sik A., Blokland A. Time-dependent involvement of cAMP and cGMP in consolidation of object memory: studies using selective phosphodiesterase type 2, 4 and 5 inhibitors. Eur. J. Pharmacol. 2007, 558:107-112.
53. Schmidt C.J., Chapin D.S., Cianfrogna J., Corman M.L., Hajos M., Harms J.F., Hoffman W.E., Lebel L.A., McCarthy S.A., Nelson F.R., Proulx-LaFrance C., Majchrzak M.J., Ramirez A.D., Schmidt K., Seymour P.A., Siuciak J.A., Tingley F.D., Williams R.D., Verhoest P.R., Menniti F.S. Preclinical characterization of selective phosphodiesterase 10A inhibitors: a new therapeutic approach to the treatment of schizophrenia. J.Pharmacol. Exp. Ther. 2008, 325:681-690.
54. Schmidt C.J. Phosphodiesterase inhibitors as potential cognition enhancing agents. Curr. Top. Med. Chem. 2010, 10:222-230.
55. Scoville W.B., Milner B. Loss of recent memory after bilateral hippocampal lesions. J.Neurol. Neurosurg. Psychiatry 1957, 20:11.
56. Selkoe D.J. Soluble oligomers of the amyloid β-protein impair synaptic plasticity and behavior. Behav. Brain Res. 2008, 192:106-113.
57. Son H., Lu Y.F., Zhuo M., Arancio O., Kandel E.R., Hawkins R.D. The specific role of cGMP in hippocampal LTP. Learn. Mem. 1998, 5:231-245.
58. Squire L.R. Memory and the hippocampus: a synthesis from findings with rats, monkeys, and humans. Psychol. Rev. 1992, 99:195-231.
59. van der Staay F.J., Rutten K., Bärfacker L., Devry J., Erb C., Heckroth H., Karthaus D., Tersteegen A., van Kampen M., Blokland A., Prickaerts J., Reymann K.G., Schröder U.H., Hendrix M. The novel selective PDE9 inhibitor BAY 73-6691 improves learning and memory in rodents. Neuropharmacology 2008, 55:908-918.
60. van Staveren W.C., Glick J., Markerink-van Ittersum M., Shimizu M., Beavo J.A., Steinbusch H.W., de Vente J. Cloning and localization of the cGMP-specific phosphodiesterase type 9 in the rat brain. J.Neurocytol. 2002, 31:729-741.
61. Verhoest P.R., Proulx-Lafrance C., Corman M., Chenard L., Helal C.J., Hou X., Kleiman R., Liu S., Marr E., Menniti F.S., Schmidt C.J., Vanase-Frawley M., Schmidt A.W., Williams R.D., Nelson F.R., Fonseca K.R., Liras S. Identification of a brain penetrant PDE9A inhibitor utilizing prospective design and chemical enablement as a rapid lead optimization strategy. J.Med. Chem. 2009, 52:7946-7949.
62. Viola K.L., Velasco P.T., Klein W.L. Why Alzheimer's is a disease of memory: the attack on synapses by Aβ oligomers (ADDLs). J.Nutr. Health Aging 2008, 12:51S-57S.
63. Walsh D.M., Selkoe D.J. Aβ oligomers-a decade of discovery. J.Neurochem. 2007, 101:1172-1184.
64. Wunder F., Tersteegen A., Rebmann A., Erb C., Fahrig T., Hendrix M. Characterization of the first potent and selective PDE9 inhibitor using a cGMP reporter cell line. Mol. Pharmacol. 2005, 68:1775-1781.
65. Yassine N., Lazaris A., Dorner-Ciossek C., Després O., Meyer L., Maitre M., Mensah-Nyagan A.G., Cassel J.C., Mathis C. Detecting spatial memory deficits beyond blindness in tg2576 Alzheimer mice. Neurobiol. Aging 2013, 34:716-730.
66. Youssef I., Florent-Béchard S., Malaplate-Armand C., Koziel V., Bihain B., Olivier J.L., Leininger-Muller B., Kriem B., Oster T., Pillot T. N-truncated amyloid-β oligomers induce learning impairment and neuronal apoptosis. Neurobiol. Aging 2008, 29:1319-1333.